If a client taking didanosine has which elevated result, the healthcare provider may consider discontinuing the medication?

Didanosine, an antiretroviral medication used primarily in the treatment of HIV, can lead to various side effects, including pancreatic toxicity. When evaluating the safety and efficacy of continuing this medication, monitoring serum amylase levels is crucial. An elevated serum amylase level may indicate the development of pancreatitis, a serious and potentially life-threatening condition that can arise from didanosine use.

Thus, if a client taking didanosine shows elevated serum amylase levels, it signals a potential risk for pancreatitis. In such cases, the healthcare provider would commonly consider discontinuing didanosine to prevent further complications and to protect the client’s health.

While other lab results like serum protein, blood glucose, and serum creatinine provide valuable information about the patient’s overall health and organ function, they do not specifically indicate an acute risk related to didanosine as strongly as elevated serum amylase levels do in the context of pancreatitis.